# Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

> **NCT05597345** · PHASE2 · RECRUITING · sponsor: **University of Rochester** · enrollment: 15 (estimated)

## Conditions studied

- Smoldering Multiple Myeloma

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT05597345
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-21
- **Primary completion:** 2024-10-29
- **Final completion:** 2025-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05597345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05597345, "Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05597345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*